Telescope Innovations (TELI) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
28 Oct, 2026Platform and market focus
Physical AI combines AI/ML experiment design, robotics, inline analytics, and closed-loop optimization for chemicals, pharmaceuticals, and critical minerals.
Self-driving labs integrate robotics, analytics, and machine learning to run continuous autonomous experiments; claimed efficiency gains include 40x energy, 4x time, and 6x space efficiency.
Intelligent automation is positioned to improve R&D throughput and quality amid cited global investments of $42B in chemicals R&D, $145B in pharma process R&D, and $2T in clean-energy R&D.
Management estimates AI-guided automation can accelerate pharma lab-to-market timelines by 10–50x and add 1–2 years of commercial monetization under patent.
Revenue model and products
Three revenue streams: contract R&D, IP licensing, and product sales, supported by a scientific team and industry relationships built over 30+ years.
DirectInject-LC automates chemical analysis; accessories, services, and software licenses create recurring revenue, with four additional products in the pipeline.
DirectInject-LC has been adopted by 15 of the top 20 pharmaceutical companies by revenue.
Global distribution agreement with Mettler-Toledo spans 100 countries; the presentation cites US$3.8B in 2023 annual sales for the distributor.
Self-driving labs and partnerships
Multi-year master collaborative research agreement with Pfizer, signed in July 2024, supports self-driving lab development; Pfizer purchased two platforms.
Platform workflows support hit screening, route narrowing, and process refinement using data-rich mapping of reaction conditions, kinetics, yield, and process sensitivity.
A Seoul installation and training in December 2025 served KPBMA, representing 300 pharmaceutical and biopharma member companies.
The partner network includes pharmaceutical, instrumentation, research, and clean-energy organizations, including Pfizer, Mettler-Toledo, Roche, Takeda, and Natural Resources Canada.
Latest events from Telescope Innovations
- SDL commercialization and DI growth underpin a forecast of cash break-even next year.TELI
Planet MicroCap Showcase: Toronto 2026 - Automation-driven R&D platforms and global partnerships fuel rapid growth and innovation.TELI
Corporate presentation - Self-driving labs and physical AI drive rapid growth and global adoption in pharma and clean tech.TELI
Planet MicroCap Las Vegas 2026 - Revenues surged 80% year-over-year, fueled by SDL growth and new major contracts.TELI
Q3 2026 - Year-to-date revenues exceeded last year's total, fueled by strong product sales and engagement.TELI
Q3 2024 - 57% revenue growth and key pharma partnerships fueled innovation and reduced EBITDA loss.TELI
Q4 2024 - Q1 revenue hit $1.2M, with strategic investments driving growth and innovation.TELI
Q1 2025 - Revenue up 46% year-over-year, with strategic growth in AI labs and battery tech.TELI
Q2 2025 - Revenue rose to $1.4M in Q3 FY2025, with strong DirectInject-LC sales and new tech milestones.TELI
Q3 2025